Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561724 | 0.84 | KDM4E (0.47) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL38661082 | 0.79 | KDM4E (0.55) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL9933881 | 0.79 | MAPT (0.50) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL19141271 | 0.79 | KDM4E (0.50) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL8371416 | 0.79 | MAPT (0.50) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL8906440 | 0.79 | KDM4E (0.50) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL8345999 | 0.79 | KDM4E (0.46) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL31556099 | 0.76 | KDM4E (0.52) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL11594753 | 0.75 | MAPT (0.46) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL7459121 | 0.75 | KDM4E (0.46) | MAPTKDM4EALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12098148-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| CN-112996785-A | Therapeutic compounds | 希四克斯探索有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3192792-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Vigonvita Life Sciences Co., Ltd. (CN) | 2017-07-19 | — | — | EP | disclosed |
| EP-0298921-B1 | 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES | CIBA-GEIGY AG (CH) | 1992-12-23 | — | — | EP | disclosed |
| EP-0325375-B1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1992-08-12 | — | — | EP | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| CN-1009831-B | PROCESS FOR PREPARING HETEROCYCLE-OXO-2,3-DIAZANAPHTHYL-ACETIC ACID | PFIZER (US) | 1990-10-03 | — | — | CN | disclosed |
| US-4957931-A | ANTICONVULSANTS, TREATMENT OF EPILEPSY | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| US-4859691-A | Certain 1,2-benzisoxazole derivatives | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0325375-A1 | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0298921-A1 | 1,2-Benzisoxazoles and 1,2-benzisothiazoles | CIBA-GEIGY AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| CN-86108308-A | Heterocycle oxo-2 guanidine-acetic acid | — | 1987-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | MAPT 572/4885KDM4E 3963/4885ALDH1A1 307/4885 |
| US-12098148-B2 | Therapeutic compounds | NFE2L2, KEAP1, NQO1 | MAPT 572/4885KDM4E 3963/4885ALDH1A1 307/4885 |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | NOTUM, ALDH7A1, HADHB | MAPT 536/4885KDM4E 890/4885ALDH1A1 955/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | MAPT 572/4885KDM4E 3963/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.